- Home
- FLYE vs BRTX Comparison
FLYE vs BRTX Comparison
Compare FLYE & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- BRTX
- Stock Information
- Founded
- FLYE 2018
- BRTX 1997
- Country
- FLYE United States
- BRTX United States
- Employees
- FLYE N/A
- BRTX N/A
- Industry
- FLYE Aerospace
- BRTX Managed Health Care
- Sector
- FLYE Industrials
- BRTX Health Care
- Exchange
- FLYE Nasdaq
- BRTX Nasdaq
- Market Cap
- FLYE 10.5M
- BRTX 12.2M
- IPO Year
- FLYE 2024
- BRTX N/A
- Fundamental
- Price
- FLYE $0.42
- BRTX $1.70
- Analyst Decision
- FLYE
- BRTX Strong Buy
- Analyst Count
- FLYE 0
- BRTX 1
- Target Price
- FLYE N/A
- BRTX $18.00
- AVG Volume (30 Days)
- FLYE 190.3K
- BRTX 34.4K
- Earning Date
- FLYE 05-10-2025
- BRTX 05-13-2025
- Dividend Yield
- FLYE N/A
- BRTX N/A
- EPS Growth
- FLYE N/A
- BRTX N/A
- EPS
- FLYE N/A
- BRTX N/A
- Revenue
- FLYE $28,547,111.00
- BRTX $401,000.00
- Revenue This Year
- FLYE N/A
- BRTX $446.88
- Revenue Next Year
- FLYE N/A
- BRTX $39.53
- P/E Ratio
- FLYE N/A
- BRTX N/A
- Revenue Growth
- FLYE N/A
- BRTX 175.03
- 52 Week Low
- FLYE $0.33
- BRTX $1.03
- 52 Week High
- FLYE $7.62
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- BRTX 46.35
- Support Level
- FLYE N/A
- BRTX $1.66
- Resistance Level
- FLYE N/A
- BRTX $1.78
- Average True Range (ATR)
- FLYE 0.00
- BRTX 0.10
- MACD
- FLYE 0.00
- BRTX -0.00
- Stochastic Oscillator
- FLYE 0.00
- BRTX 44.37
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.